When surveying the outcome in different cancers across the TCGA cohort, we found the consequences of HemDel loss were more pronounced in some tumor types, suggesting that other cellular contexts or unknown tumor-specific molecular features may contribute to progression when PTEN is partially deficient. The gene discussed is PTEN; the disease is neoplasm.